Recent Research Analysts’ Ratings Changes for IDEAYA Biosciences (IDYA)

A number of research firms have changed their ratings and price targets for IDEAYA Biosciences (NASDAQ: IDYA):

• 6/13/2026 – IDEAYA Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/12/2026 – IDEAYA Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $58.00 price target on the stock.
• 6/2/2026 – IDEAYA Biosciences had its “market outperform” rating reaffirmed by Citigroup Inc..
• 6/2/2026 – IDEAYA Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $58.00 price target on the stock.
• 5/23/2026 – IDEAYA Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/22/2026 – IDEAYA Biosciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/7/2026 – IDEAYA Biosciences had its price target lowered by Mizuho from $52.00 to $50.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – IDEAYA Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/18/2026 – IDEAYA Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.